Levalbuterol Tartrate Patent Expiration
Levalbuterol Tartrate is Used for managing asthma symptoms and bronchospasms. It was first introduced by Lupin Inc
Levalbuterol Tartrate Patents
Given below is the list of patents protecting Levalbuterol Tartrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xopenex Hfa | US7256310 | Levalbuterol salt |
Oct 08, 2024
(Expired) | Lupin |
| Xopenex Hfa | US8765153 | Levalbuterol salt |
Dec 08, 2023
(Expired) | Lupin |
| Xopenex Hfa | US5836299 | Seals for use in an aerosol delivery device |
Nov 17, 2015
(Expired) | Lupin |
| Xopenex Hfa | US5605674 | Medicinal aerosol formulations |
Feb 25, 2014
(Expired) | Lupin |
| Xopenex Hfa | US5547994 | Method for treating asthma using optically pure R(-) albuterol |
Aug 20, 2013
(Expired) | Lupin |
| Xopenex Hfa | US5362755 | Method for treating asthma using optically pure (R)-albuterol |
Mar 25, 2013
(Expired) | Lupin |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Levalbuterol Tartrate's patents.
Latest Legal Activities on Levalbuterol Tartrate's Patents
Given below is the list recent legal activities going on the following patents of Levalbuterol Tartrate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jan, 2022 | US8765153 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Feb, 2019 | US7256310(Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Jan, 2018 | US8765153 |
| Application ready for PDX access by participating foreign offices Critical | 31 Aug, 2015 | US8765153 |
| Post Issue Communication - Certificate of Correction | 13 Aug, 2014 | US8765153 |
| Recordation of Patent Grant Mailed Critical | 01 Jul, 2014 | US8765153 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Jul, 2014 | US8765153 |
| Issue Notification Mailed Critical | 11 Jun, 2014 | US8765153 |
| Dispatch to FDC | 02 Jun, 2014 | US8765153 |
| Mail Response to 312 Amendment (PTO-271) Critical | 02 Jun, 2014 | US8765153 |
Levalbuterol Tartrate's Family Patents
